Research Grade Alteplase

Catalog No.	HF934026
Brand	abinScience
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS pH 7.4
Purity	>95% purity as determined by SDS-PAGE.
Isotype	Recombinant tissue plasminogen activator (rt-PA) with C-terminal 6*His
Applications	ELISA, Functional assay, Research in vivo
Target	Tissue-type plasminogen activator, t-PA, t-plasminogen activator, tPA, 3.4.21.68, Alteplase, Reteplase, Tissue-type plasminogen activator chain A, Tissue-type plasminogen activator chain B, PLAT
References	1. J Bastecký, et al. [Actilyse (a recombinant tissue-type plasminogen activator] in the treatment of acute myocardial infarct. Comparison of the effects of Actilyse and streptokinase]. Vnitr Lek. 1994 May;40(5):293-8. [HF934026] 2. Micieli G, et al. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag. 2009;5(1):397-409. [HF934026] 3. Orset C, et al. Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis. Stroke. 2016 May;47(5):1312-1318. [HF934026] 4. Kimura S, et al. Cytotoxic effects of alteplase, a recombinant tissue plasminogen activator, on human retinal pigment epithelial cells. Jpn J Ophthalmol. 2021 Sep;65(5):731-739. View More [HF934026]
Purification	Purified by Nickel column.
Biological activity	Alteplase (8.3 and 250 ug/mL, 12 h) shows a signifcant reduction in viability of human fetal retinal pigment epithelial (hfRPE cells) [4]. Alteplase (8.3 and 250 ug/mL, 0-6 h) signifcantly decreases the transepithelial resistance in a time-dependent manner and induces cell death in hfRPE cells [4]. Alteplase (0.9-10 mg/kg, i.v.
Endotoxin level	< 10 EU/mg
Expression system	Mammalian cells
Accession	P00750
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative name	105857-23-6
Note	For research use only. Not suitable for clinical or therapeutic use.